(NASDAQ: CORT) Corcept Therapeutics's forecast annual revenue growth rate of 13.45% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.35%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.76%.
Corcept Therapeutics's revenue in 2024 is $523,529,000.On average, 4 Wall Street analysts forecast CORT's revenue for 2024 to be $64,907,119,582, with the lowest CORT revenue forecast at $63,416,755,043, and the highest CORT revenue forecast at $66,715,025,990. On average, 4 Wall Street analysts forecast CORT's revenue for 2025 to be $67,027,049,918, with the lowest CORT revenue forecast at $57,920,677,917, and the highest CORT revenue forecast at $73,711,358,304.
In 2026, CORT is forecast to generate $82,365,155,059 in revenue, with the lowest revenue forecast at $81,824,813,322 and the highest revenue forecast at $83,352,137,653.